Lipocine vs Rani Therapeutics
LPCN and RANI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LPCN and RANI compare
Rani Therapeutics is the larger company, worth 5.2 times as much as Lipocine ($73.4M against $14.1M).
Rani Therapeutics grew revenue faster over the last twelve months (449% versus −13.4% for Lipocine).
Lipocine keeps more of each dollar of sales as profit, with a net margin of −249% compared with −493% at Rani Therapeutics.
Lipocine scores higher on the StockData Score (11 against 2 for Rani Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LPCN | RANI |
|---|---|---|
| Size and price | ||
| Market cap | $14.1M | $73.4M |
| Share price | $1.71 | $0.526 |
| Change, 1 year | −41.4% | −75.2% |
| Change, 5 years | −91.4% | −98.5% |
| Beta (5Y) | 0.66 | 0.85 |
| Employees | 14 | 69 |
| StockData Score | ||
| Total score | 11 (better) | 2 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.8× (better) | 11.1× |
| P/B | 0.7× (better) | 2.2× |
| FCF yield | – | −31.7% |
| Fair value | $3.29 | $0.366 |
| Margin of safety | 48.0% (better) | −43.8% |
| Growth | ||
| Revenue growth (TTM) | −13.4% | 449% (better) |
| Revenue growth, 5Y average | – | 28.7% |
| Profitability | ||
| Operating margin | −269% (better) | −530% |
| Net margin | −249% (better) | −493% |
| FCF margin | – | −353% |
| Return on equity | −52.9% (better) | −249% |
| Return on invested capital | – | −173% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −71.9× |
| Current ratio | 11.36 (better) | 5.26 |
| Altman Z-score | −9.08 | −1.36 (better) |
| Piotroski F-score | 1 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −114% | – |
| Shareholder yield | −114% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 36.2% | 32.7% |
| Held by insiders | 8.4% | 30.6% |
| Insider net buying, 12 months | $517K (better) | $49.7K |
| Short interest, % of float | 4.3% | 8.5% |
Go deeper
- LPCN stock overview
- LPCN income statement
- LPCN valuation and score
- RANI stock overview
- RANI income statement
- RANI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.